Sorrento Therapeutics

Company

Investment-firm

Last deal

$25M

Amount

Post-IPO Equity

Stage

09.10.2019

Date

3

all rounds

$264.42M

Total amount

Financing round

General

About Company
Sorrento Therapeutics is a biopharmaceutical company developing innovative therapies for cancer, autoimmune diseases and pain management.

Related to

Sorrento Therapeutics

Sorrento Therapeutics

Sorrento Therapeutics is a biopharmaceutical company developing innovative therapies for cancer, autoimmune diseases and pain management.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Diego, CA, USA

total rounds

8

total raised

$264.42M

count Of Investments

5

count Of Exists

1

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2006

founders

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's portfolio includes a diverse range of assets such as antibodies, CAR-T cells, antibody drug conjugates, and an oncolytic virus. They are also developing pain management solutions and conducting clinical studies for potential COVID-19 therapies and vaccines. Sorrento Therapeutics aims to address unmet medical needs and improve patient outcomes through their targeted delivery modalities and proprietary technologies.
Contacts

Contact Email

Phone number

Social url

Sub-Organizations
2

TNK Therapeutics

TNK Therapeutics is a company focused on developing immunotherapy programs using chimeric antigen receptors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Diego, CA, USA
Sorrento Therapeutics

Sorrento Therapeutics

Sorrento Therapeutics is a biopharmaceutical company developing innovative therapies for cancer, autoimmune diseases and pain management.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Diego, CA, USA

total rounds

8

total raised

$264.42M

count Of Investments

5

count Of Exists

1
Similar Companies
1000
Trigr Therapeutics

Trigr Therapeutics

TRIGR Therapeutics is a privately-owned company that develops next-generation cancer therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

Irvine, CA, USA
Ziopharm oncology

Ziopharm oncology

ZIOPHARM Oncology is a biotechnology company developing gene therapy, cell therapy, and cancer immunotherapy products.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

New York, NY, USA

total rounds

9

total raised

$293.39M
Virios Therapeutics

Virios Therapeutics

Virios Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Alpharetta, GA, USA

total rounds

5

total raised

$12.94M
Enliven Therapeutics

Enliven Therapeutics

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Boulder, CO, USA

total rounds

5

total raised

$395M

Financials

Funding Rounds
8
3

Number of Funding Rounds

$264.42M

Money Raised

Their latest funding was raised on 09.10.2019. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
09.10.2019
$25M
28.11.2016
$75M
Ally Bridge Group

Ally Bridge Group

Ally Bridge Group is a global healthcare-focused investment group.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Finance

Location

Hong Kong Island, Hong Kong

count Of Investments

77

count Of Exists

4
Investments
5
Date 
name 
Lead 
type 
Raised 
Aardvark Therapeutics

Aardvark Therapeutics

Aardvark Therapeutics develops small molecule therapeutics for obesity and rare genetic metabolic disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Health Care

Location

San Diego, CA, USA

total rounds

3

total raised

$129M
Celularity

Celularity

Celularity is a clinical stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Florham Park, NJ, USA

total rounds

4

total raised

$400M
Celularity

Celularity

Celularity is a clinical stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Florham Park, NJ, USA

total rounds

4

total raised

$400M
Co-Investors
Investors
1
1

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Post-IPO Equity
Ally Bridge Group

Ally Bridge Group

Ally Bridge Group is a global healthcare-focused investment group.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Finance

Location

Hong Kong Island, Hong Kong

count Of Investments

77

count Of Exists

4
Acquisitions
6

Ancora Medical Technology acquired by Sorrento Therapeutics

acquirer

Sorrento Therapeutics
Sorrento Therapeutics

date

07.07.2022

type

Acquisition

Ancora Medical Technology

Ancora Medical is a privately held medical technology company.

Sector

Medical Equipment and Services

Subsector

Medical Equipment

Keywords

Medical, Medical Device, Health Care

Location

Delaware, ON N0L, Canada
Virex Health acquired by Sorrento Therapeutics

Virex Health acquired by Sorrento Therapeutics

acquirer

Sorrento Therapeutics
Sorrento Therapeutics

date

01.02.2022

type

Acquisition
Virex Health

Virex Health

Virex is a biotech company revolutionizing global testing across various settings.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Diagnostics, Health Care, Medical Device

Location

Wellesley Hills, Wellesley, MA 02481, USA

total rounds

1

total raised

$510K
ACEA Therapeutics acquired by Sorrento Therapeutics

ACEA Therapeutics acquired by Sorrento Therapeutics

acquirer

Sorrento Therapeutics
Sorrento Therapeutics

date

05.04.2021

price

$38M
ACEA Therapeutics

ACEA Therapeutics

ACEA Therapeutics develops innovative treatments for life-threatening diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Diego, CA, USA
Exits
1

NantiBodyFc

NantiBodyFc is a healthcare company based in Cumming, Georgia.

Sector

Health Care Providers

Subsector

Health Care Management Services

Keywords

Health Care, Biotechnology, Medical

Location

Cumming, GA, USA

total rounds

2

total raised

$50.44M

People

Founders
1
Henry Ji
Henry Ji

Henry Ji

Dr. Ji’s extensive knowledge of the industry in which we operate, as well as his unique role in our day-to-day operations as our Chief Executive Officer and President, allows him to bring to our board of directors a broad understanding of the operational and strategic issues we face. Dr. Ji also served as Sorrento’s Secretary from September 2009 to June 2011, Chief Scientific Officer from November 2008 to September 2012, and as its Interim Chief Executive Officer from April 2011 to September 2012. In 2002, Dr. Ji founded BioVintage, Inc., a research and development company focusing on innovative life science technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr. Ji served as Vice President of CombiMatrix Corporation, a publicly traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr. Ji served as Director of Business Development, and in 2001 as Vice President, of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr. Ji co-founded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr. Ji is the holder of several issued and pending patents in the life science field and is the sole inventor of Sorrento Inc.’s intellectual property covering the G-MAB® library technology. Dr. Ji obtained his Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University.

current job

Sorrento Therapeutics
Sorrento Therapeutics

Henry Ji

Employee Profiles
41

Haining Huang

President and cso, cytimm therapeutics

Robert Allen

Robert Allen

Vice President Antiviral and oncolytic immunotherapy development

Lauren Ruth

Senior accountant

Daniel Tomko

Senior director of quality

Emmy Bashi

Emmy Bashi

Senior Accountant

Clarissa Martin

Cell therapy

Yang Wang

Scientist

Brian Cooley

Senior vice president, devices and diagnostifcs

Activity

Recent News
9
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month